Cogent Biosciences Q3 net loss widens on higher expenses
Overview
U.S. biotech firm reported Q3 net loss widened to $111.4 mln as expenses rose
Company's R&D and G&A expenses increased due to clinical trials and commercial launch readiness
Cash balance of $791.1 mln expected to fund operations into late 2028
Outlook
Company expects potential FDA approval of bezuclastinib in GIST by Nov. 30, 2026
Potential FDA approval of bezuclastinib in NonAdvSM expected by Dec. 30, 2026
Potential FDA approval of bezuclastinib in AdvSM expected by June 29, 2027
Result Drivers
R&D SPENDING - Higher research and development expenses driven by ongoing SUMMIT, PEAK and APEX clinical trials and early-stage pipeline programs
COMMERCIAL READINESS - Increased general and administrative costs attributed to investments in commercial readiness and organizational growth
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $111.43 mln | ||
Q3 Income from Operations | -$117.18 mln | ||
Q3 Operating Expenses | $117.18 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cogent Biosciences, Inc. is $55.00, about 74.7% above its November 4 closing price of $31.49
Reuters Recommended Reads
Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs
Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs
Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)